EASL 2013: Daclatasvir plus Interfero...

EASL 2013: Daclatasvir plus Interferon Cures More Genotype 2/3 Hepatitis C Patients

There are 1 comment on the HIV and Hepatitis story from May 4, 2013, titled EASL 2013: Daclatasvir plus Interferon Cures More Genotype 2/3 Hepatitis C Patients. In it, HIV and Hepatitis reports that:

Adding the HCV NS5A inhibitor daclatasvir to pegylated interferon and ribavirin for 12 or 16 weeks led to higher response rates for previously untreated people with genotype 2 or 3 hepatitis C, according to results from the COMMAND study reported last week at the EASL International Liver Congress in Amsterdam.

Join the discussion below, or Read more at HIV and Hepatitis.



#1 May 4, 2013
This disease is now cured in most people with this treatment, what a great job by the medical researchers

Tell me when this thread is updated:

Subscribe Now Add to my Tracker

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

Hepatitis Discussions

Title Updated Last By Comments
News Should state mandate immunizations? New require... (May '11) Jul 15 BackwoodsBarbie423 9,774
Rebuttal over Cochrane Review of DAAs-What is t... Jul 8 hcvnewdrugs 1
News Scientific Evidence and the EU Court Jul 6 VAERS NVICP 1
The Liver - Super Foods & Supplements Jun 30 hcvnewdrugs 1
News EU court: Vaccines can be blamed for illnesses ... Jun 21 RIGHT ON 2
News Burlington dental patients told to get tested f... Jun '17 Lenny 1
News The opioid epidemic is making the fight against... Jun '17 Ronald 2
More from around the web